The historical rank and industry rank for Agios Pharmaceuticals's FCF Margin % or its related term are showing as below:
FRA:8AP'
s FCF Margin % Range Over the Past 10 Years
Min: -2207.58 Med: -716.84 Max: 40.99
Current: -597.82
During the past 13 years, the highest FCF Margin % of Agios Pharmaceuticals was 40.99%. The lowest was -2207.58%. And the median was -716.84%.
FRA:8AP's FCF Margin % is ranked worse than 74.27% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs FRA:8AP: -597.82
Agios Pharmaceuticals FCF Margin % Related Terms
Agios Pharmaceuticals FCF Margin % Historical Data
* Premium members only.
The historical data trend for Agios Pharmaceuticals's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8AP vs CAPR, SNDX, SLS: FCF Margin % Comparison
For the Biotechnology subindustry, Agios Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agios Pharmaceuticals FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Agios Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agios Pharmaceuticals (FRA:8AP) has a FCF Margin % of -576.94% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Agios Pharmaceuticals and its competitors. According to the industry distribution chart, Agios Pharmaceuticals ranks #713 out of 960 companies in the Biotechnology industry, placing it in the top 74.3%.
Is Agios Pharmaceuticals' FCF Margin % too high?
Agios Pharmaceuticals' current FCF Margin % is -576.94%. Based on the distribution chart, Agios Pharmaceuticals ranks #713 out of 960 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Agios Pharmaceuticals has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' FCF Margin % compare to CAPR and SNDX?
According to the Biotechnology industry distribution chart, Agios Pharmaceuticals ranks #713 out of 960 companies for FCF Margin %. This places Agios Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current FCF Margin % is -576.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Agios Pharmaceuticals (FRA:8AP) is currently considered Possible Value Trap. The stock's GF Value™ is €70.71, compared to a current price of €32.00 — trading 54.7% below its estimated fair value. The current FCF Margin % is -576.94%. Agios Pharmaceuticals' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current FCF Margin % is -576.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?
Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued.
The current stock price of €32.00 is trading 54.7% below its estimated GF Value™ of €70.71.
GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.
Key valuation signals for FRA:8AP:
FCF Margin %: -576.94%
GF Value™: €70.71 vs. price of €32.00 (54.7% below fair value)
No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
44GF Score
Get the complete analysis for FRA:8AP
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8AP has been successfully added to your 
